Bladder Cancer: Avelumab Maintenance Shows Benefit for Both Patients With and Without Diabetes Mellitus
In this MEDtalk, Dr. Petros Grivas presents the long-term outcomes from the JAVELIN Bladder 100 trial, discussing the impact of avelumab as first-line maintenance therapy for advanced urothelial carcinoma in patients with and without diabetes.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
